Stem cell breakthrough heralds new era of therapy development
18 July 2011
Researchers funded by BBSRC and the University of Glasgow have used knowledge of cell biology and engineering to uncover a new method for growing sufficient adult stem cells for therapeutic use. This could help the progress of developments in stem cell therapies for conditions such as arthritis, Alzheimer's disease and Parkinson's disease.
The research, carried out at the Universities of Glasgow and Southampton, and published in the journal Nature Materials, shows how a new nanoscale plastic can cheaply and easily solve a problem which has previously made the expansion of stem cells for therapeutic purposes impossible.
Currently, when adult stem cells are harvested from a patient, they are cultured in the laboratory to increase the initial yield of cells and create a batch of sufficient volume to kick-start the process of cellular regeneration when they are reintroduced back into the patient.
The process of culturing is made more difficult by spontaneous stem cell differentiation, where stem cells grown on standard plastic tissue culture surfaces do not expand to create new stem cells but instead create other cells which are of no use in therapy. Currently, stem cell expansion is often boosted by immersing the cells in chemical solutions which help to increase the overall yield of stem cells but are limited in their effectiveness.
The new nanopatterned surface, developed and fabricated at the University of Glasgow, is designed to offer a method of stem cell expansion which is much easier to manufacture and use than anything currently available. Created by an injection-moulding process similar to that which is used to manufacture Blu-ray discs, the surface is covered with 120-nanometre pits which the researchers have found is much more effective in allowing stem cells to grow and spread whilst retaining their stem cell characteristics.
Dr Matthew Dalby from the University of Glasgow, who led the research alongside colleague Dr Nikolaj Gadegaard and Prof Richard Oreffo of the University of Southampton, said: "Until now, it's been very difficult to grow stem cells in sufficient numbers and maintain them as stem cells for use in therapy. What we and our colleagues at the University of Southampton have shown is that this new nanostructured surface can be used to very effectively culture mesencyhmal stem cells, taken from sources such as bone marrow, which can then be put to use in musculoskeletal, orthopaedic and connective tissues.
"If the same process can be used to culture other types of stem cells too, and this research in under way in our labs, our technology could be the first step on the road to developing large-scale stem cell culture factories which would allow for the creation of a wide range of therapies for many common diseases such as diabetes, arthritis, Alzheimer's disease and Parkinson's disease. We're very excited about the potential applications of the technology and we're already in the early stages of conversations to make the surface commercially available."
Professor Richard Oreffo, who led the University of Southampton team, added: "Development of platform technologies that allow the scale up of skeletal or mesenchymal stem cells offers a whole new approach to skeletal regenerative medicine. If this new technology enables us to create sufficient stem cells, and to pattern hip implants for example, it could herald the development of new medical devices with therapeutic application and approaches to understanding stem cell fate and regulation.
"It is important to realise the ability to retain skeletal stem cell phenotype using surface topography offers a step change in current approaches for stem cell biology. The implications for research and future interventions for patients with arthritis and other musculoskeletal diseases are substantial."
Professor Douglas Kell, Chief Executive, BBSRC said, "Understanding how stem cells are affected by their environment is key to appreciating how they might be grown in sufficient quantities to be used in research or as therapies. This research shows that the physical surface that the cells are grown on can actually affect their fundamental biology in ways that are useful for us.
"Multidisciplinary research is increasingly important and this project is a great example where cell biology, medicine, and engineering come together in powerful synergy to solve a complex problem."
The paper, titled 'Nanoscale surfaces for the long-term maintenance of mesenchymalstem cell phenotype and multipotency', is published in the journal Nature Materials.
Notes to editors
For further information or to request an interview with Dr Matthew Dalby or/and Dr Nikolaj Gadegaard please contact Peter Aitchison, Media Relations Manager at the University of Glasgow: tel 0141 330 3535, email email@example.com .
Professor Richard Oreffo can be contacted via Sophie Docker, Media Relations Officer at the University of Southampton: tel 023 8059 8933, email S.Docker@soton.ac.uk.
BBSRC is the UK funding agency for research in the life sciences and the largest single public funder of agriculture and food-related research.
Sponsored by Government, BBSRC’s budget for 2011-12 is around £445M which it is investing in a wide range of research that makes a significant contribution to the quality of life in the UK and beyond and supports a number of important industrial stakeholders, including the agriculture, food, chemical, healthcare and pharmaceutical sectors.
BBSRC provides institute strategic research grants to the following:
- The Babraham Institute
- Institute for Animal Health
- Institute of Biological, Environmental and Rural Sciences (Aberystwyth University)
- Institute of Food Research
- John Innes Centre
- The Genome Analysis Centre
- The Roslin Institute (University of Edinburgh)
- Rothamsted Research
The Institutes conduct long-term, mission-oriented research using specialist facilities. They have strong interactions with industry, Government departments and other end-users of their research.